Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study

Authors: Shuai Hao, Rongkun Luo, Wei Li, Ruhan Zhao, Tong Qi, Zichen Wang, Nan Li, Ming Liu

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Objective

To construct a survival prediction model for patients with TNM stage III hepatocellular carcinoma (HCC) to guide the clinical diagnosis and treatment of HCC patients and improve prognosis.

Methods

Based on data from patients with stage III (AJCC 7th TNM stage) recorded by the American Institute of Cancer Research from 2010 to 2013, risk factors affecting the prognosis were screened by Cox univariate and multivariate regression, line plots was constructed, and the credibility of the model was verified by Boostrap method. ROC operating curves, calibration curves and DCA clinical decision curves were used to evaluate the model, and Kaplan–Meier was used for survival analysis was used to evaluate the efficacy of the model. External survival data from patients newly diagnosed with stage III hepatocellular carcinoma during 2014–2015 were used to validate and fit the model and to optimize the model.

Results

Age > 75 years vs.18-53 years [HR = 1.502; 95%CI(1.134–1.990)], stage IIIC vs. Stage IIIA [HR = 1.930; 95%CI(1.509–2.470)], lobotomy vs. non-surgery [HR = 0.295; 95%CI(0.228–0.383)], radiotherapy vs. non-radiotherapy [HR = 0.481; 95%CI(0.373–0.619)], chemotherapy vs. Non-chemotherapy [HR = 0.443; 95%CI(0.381–0.515)], positive serum AFP before treatment vs. negative [HR = 1.667; 95%CI(1.356–2.049)], the above indicators are independent prognostic factors for patients with stage III hepatocellular carcinoma, and the P values for the above results were less than 0.05. A joint prediction model was constructed based on age, TNM stage, whether and how to operate, whether to receive radiotherapy, whether to receive chemotherapy, pre-treatment serum AFP status and liver fibrosis score. The consistency index of the improved prognosis model was 0.725.

Conclusions

The traditional TNM staging has limitations for clinical diagnosis and treatment, while the Nomogram model modified by TNM staging has good predictive efficacy and clinical significance.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Feng J, He Y, Wan J, et al. Pulmonary metastases in newly diagnosed hepatocellular carcinoma: a population-based retrospective study. HPB (Oxford). 2020;22(9):1295–304.CrossRefPubMed Feng J, He Y, Wan J, et al. Pulmonary metastases in newly diagnosed hepatocellular carcinoma: a population-based retrospective study. HPB (Oxford). 2020;22(9):1295–304.CrossRefPubMed
3.
go back to reference Jun L, Zhenlin Y, Renyan G, et al. Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist. 2012;17(7):963–9.CrossRefPubMedPubMedCentral Jun L, Zhenlin Y, Renyan G, et al. Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist. 2012;17(7):963–9.CrossRefPubMedPubMedCentral
4.
go back to reference Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28(9):1256–63.CrossRefPubMed Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28(9):1256–63.CrossRefPubMed
5.
go back to reference Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202.CrossRefPubMed Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202.CrossRefPubMed
6.
go back to reference Hong SS, Kim TK, Sung KB, et al. Extrahepatic spread of hepatocellular carcinoma: a pictorial review. Eur Radiol. 2003;13(4):874–82.CrossRefPubMed Hong SS, Kim TK, Sung KB, et al. Extrahepatic spread of hepatocellular carcinoma: a pictorial review. Eur Radiol. 2003;13(4):874–82.CrossRefPubMed
7.
go back to reference Chen X, Lu Y, Shi X, et al. Epidemiological and clinical characteristics of five rare pathological subtypes of hepatocellular carcinoma. Front Oncol. 2022;8(12):864106.CrossRef Chen X, Lu Y, Shi X, et al. Epidemiological and clinical characteristics of five rare pathological subtypes of hepatocellular carcinoma. Front Oncol. 2022;8(12):864106.CrossRef
8.
go back to reference Chen H, Zhuang H. Current status of chronic hepatitis B epidemiology in China. Hepatol. 2018;01:8–9. Chen H, Zhuang H. Current status of chronic hepatitis B epidemiology in China. Hepatol. 2018;01:8–9.
9.
go back to reference Wang Y. Study on the prognostic value of radiotherapy in giant hepatocellular carcinoma and construction of a graph model. China: Fujian Medical University; 2021. Wang Y. Study on the prognostic value of radiotherapy in giant hepatocellular carcinoma and construction of a graph model. China: Fujian Medical University; 2021.
10.
go back to reference Zongyi G, Chenglong M, Hong Z, et al. Application of optimal radiotherapy based on subhepatic segment functional unit protection in precision radiotherapy for liver cancer. Chin J Med Sci. 2002;12(04):165–8. Zongyi G, Chenglong M, Hong Z, et al. Application of optimal radiotherapy based on subhepatic segment functional unit protection in precision radiotherapy for liver cancer. Chin J Med Sci. 2002;12(04):165–8.
11.
go back to reference Sacco R, Ramai D, Tortora R, et al. Role of etiology in hepatocellular carcinoma patients treated with Lenvatinib: a counterfactual event-based mediation analysis. Cancers (Basel). 2023;15(2):381.CrossRefPubMed Sacco R, Ramai D, Tortora R, et al. Role of etiology in hepatocellular carcinoma patients treated with Lenvatinib: a counterfactual event-based mediation analysis. Cancers (Basel). 2023;15(2):381.CrossRefPubMed
12.
go back to reference Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.CrossRefPubMed Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.CrossRefPubMed
13.
go back to reference A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hep. 1998;28(3):751-5. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hep. 1998;28(3):751-5.
14.
go back to reference Agarwal R, Narayan J, Bhattacharyya A, Saraswat M, Tomar AK. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet. 2017;216-217:37-51. Agarwal R, Narayan J, Bhattacharyya A, Saraswat M, Tomar AK. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet. 2017;216-217:37-51.
15.
go back to reference Zhang H, Du X, Dong H, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348.CrossRefPubMedPubMedCentral Zhang H, Du X, Dong H, et al. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol. 2022;22(1):348.CrossRefPubMedPubMedCentral
16.
go back to reference Wang Dongmei, Gao Shile, Lu Donghui, et al. Analysis of the effect of radiotherapy on primary hepatocellular carcinoma and the related factors of radioactive liver injury. J Anhui Med. 2022;26(02):243-246 Wang Dongmei, Gao Shile, Lu Donghui, et al. Analysis of the effect of radiotherapy on primary hepatocellular carcinoma and the related factors of radioactive liver injury. J Anhui Med. 2022;26(02):243-246
17.
go back to reference Li Guangxiao, Xiao Peng, ZHEN Yulan, et al. Influence factors of intensity modulated radiotherapy combined with hepatic artery chemoembolization in the treatment of hepatocellular carcinoma complicated with portal vein cancer thrombus. Chin Med Guide. 2021;19(23):1–3. Li Guangxiao, Xiao Peng, ZHEN Yulan, et al. Influence factors of intensity modulated radiotherapy combined with hepatic artery chemoembolization in the treatment of hepatocellular carcinoma complicated with portal vein cancer thrombus. Chin Med Guide. 2021;19(23):1–3.
18.
go back to reference Ya RH, Guy DE. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and metaanalysis. JAMA Oncol. 2015;1(6):756–65.CrossRef Ya RH, Guy DE. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and metaanalysis. JAMA Oncol. 2015;1(6):756–65.CrossRef
19.
go back to reference Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754.CrossRefPubMedPubMedCentral Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754.CrossRefPubMedPubMedCentral
20.
go back to reference Ryoko Y. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–94.CrossRef Ryoko Y. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–94.CrossRef
21.
go back to reference Jordi B, et al. Prognostic factors and predictors of sorafenib beneft in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999–1008.CrossRef Jordi B, et al. Prognostic factors and predictors of sorafenib beneft in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999–1008.CrossRef
22.
go back to reference Luo P, Wu S, Yu Y, et al. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26(2):599–603.CrossRefPubMed Luo P, Wu S, Yu Y, et al. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26(2):599–603.CrossRefPubMed
23.
24.
go back to reference Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.CrossRefPubMed Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.CrossRefPubMed
25.
go back to reference Lin E, Zou B, Zeng G, et al. The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Ann Transl Med. 2021;9(16):1310.CrossRefPubMedPubMedCentral Lin E, Zou B, Zeng G, et al. The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Ann Transl Med. 2021;9(16):1310.CrossRefPubMedPubMedCentral
26.
go back to reference Stefanini B, Ielasi L, Chen R, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.CrossRefPubMed Stefanini B, Ielasi L, Chen R, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.CrossRefPubMed
27.
go back to reference D’Avola D, Granito A, Torre-Aláez M, et al. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–98.CrossRefPubMed D’Avola D, Granito A, Torre-Aláez M, et al. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–98.CrossRefPubMed
28.
go back to reference Yao J, Liang X, Liu Y, et al. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control. 2022;29:10732748211051548.CrossRefPubMedPubMedCentral Yao J, Liang X, Liu Y, et al. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control. 2022;29:10732748211051548.CrossRefPubMedPubMedCentral
29.
go back to reference Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.CrossRefPubMed Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.CrossRefPubMed
30.
go back to reference Smith SM, Stinson FS, Dawson DA, et al. Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Psychol Med. 2006;36(7):987–98.CrossRefPubMed Smith SM, Stinson FS, Dawson DA, et al. Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Psychol Med. 2006;36(7):987–98.CrossRefPubMed
31.
go back to reference Satriano L, Lewinska M, Rodrigues PM, et al. Metabolic rearrangements in primary liver cancers: Cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–66.CrossRefPubMed Satriano L, Lewinska M, Rodrigues PM, et al. Metabolic rearrangements in primary liver cancers: Cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–66.CrossRefPubMed
32.
go back to reference Zhang JF, Shu ZJ, Xie CY, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9(3):e88182.CrossRefPubMedPubMedCentral Zhang JF, Shu ZJ, Xie CY, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9(3):e88182.CrossRefPubMedPubMedCentral
Metadata
Title
Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study
Authors
Shuai Hao
Rongkun Luo
Wei Li
Ruhan Zhao
Tong Qi
Zichen Wang
Nan Li
Ming Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02820-5

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.